The sale of diet drug rimonabant (Acomplia / Zimulti) during the period of first three months of 2007 were 15 million Euros which was not a satisfactory sale of the expensive weight loss diet pill. European refusal of repayment of insurance affected the sale of the weight loss pill.
According to Sanofi more than 130,000 overweight and obese people have consumed the weight loss pill in
Analysts said, “The number suggested that many apparently have sampled the diet drug and discontinued use, since at its European price, continuous use by fewer than half that number of Europeans would have produced a higher quarterly sales figure.”
The Government authorities either refused to compensate to patients for acomplia or had a limited refund for the expensive weight loss pill to obese patients suffering from uncontrolled type 2 diabetes.
The conference call of analysts, Sanofi executive vice president Hanspeter Spek confirmed the faith of company to sell diet drug under the trade name Zimulti in the United Satate’s market by the end of the year.
FDA advisory panel air the safety concerns about the deit drug on June 13.
It is predicted that a final decision will be taken by U.S regulatory on approval of rimonabant before the end of july.
No comments:
Post a Comment